Logo

Rallybio Partners with Johnson & Johnson on Therapeutic Solutions to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Share this
Rallybio

Rallybio Partners with Johnson & Johnson on Therapeutic Solutions to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Shots:

  • Rallybio has partnered with J&J to develop therapeutic solutions for preventing fetal & neonatal alloimmune thrombocytopenia (FNAIT) as well as secured $6.6M equity 
  • Under the partnership, J&J will fund Rallybio to promote its FNAIT clinical program in conjunction with Rallybio’s current FNAIT natural history study. Rallybio is entitled to receive additional payments
  • Rallybio's natural history study aims to gather dataset for HPA-1a alloimmunization frequency among populations to support RLYB212’s (human monoclonal anti-HPA-1a Ab) registration trial. RLYB212’s P-II dose confirmation trial in pregnant individuals at higher risk of alloimmunization & FNAIT is anticipated in H2’24

Ref: Rallybio Image: Rallybio

Related News:- Rallybio Presents P-I Single Ascending Dose Results of RLYB116 for Complement-Mediated Diseases at ICW 2023

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions